Category - Developments

Developments

Myovant’s relugolix meets primary endpoint in Phase 3 uterine fibroid trial

Myovant Sciences (NASDAQ:MYOV) reported that the second of two Phase 3 studies of relugolix met its primary efficacy endpoint and six key secondary endpoints in women with uterine fibroids. Relugolix is a once daily...

July 24, 2019

Developments

Theralase in pact for U.S. clinical sites for Phase 2 NMIBC trial

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) signed an agreement with a trial management organization (TMO) to provide four-to-six U.S.-based urology study sites that will be able to commence enrolling and treating...

July 24, 2019

Developments

Dawson James starts Anavex at buy: PT $16

Dawson James initiated coverage of Anavex Life Sciences (NASDAQ:AVXL) with a “buy” rating and $16 price target. The stock closed $2.54 on July 23. Anavex is pioneering a new treatment in CNS diseases like...

July 24, 2019

Developments

Zenabis outperforms cannabis design capacity by 41% in June

Zenabis Global (TSX:ZENA) reported that its cultivation output in June 2019 was 756 kg of dried cannabis, which represents a 40.8% outperformance relative to design capacity, or a performance ratio of 40.8%. June 2019...

July 24, 2019

Developments

Chiasma’s Mycapssa meets all endpoints in Phase 3 acromegaly trial

Chiasma (NASDAQ:CHMA) reported positive top-line Phase 3 data from a pivotal trial evaluating its octreotide candidate, conditionally trade-named Mycapssa, for the treatment of acromegaly. Acromegaly is caused by the...

July 23, 2019

Developments

Emerging liver disease company, ContraVir, changes name to Hepion Pharmaceuticals; stock symbol to “HEPA”

ContraVir Pharmaceuticals (NASDAQ:CTRV) announced a name change to Hepion Pharmaceuticals, and a stock symbol change to “HEPA,” effective as of opening of trading on July 23, 2019. “We derived the name “Hepion” by...

July 22, 2019

Developments

Intec Parkinson’s disease candidate misses primary endpoint in Phase 3 trial

Intec Pharma (NASDAQ:NTEC) reported that its Accordion Pill carbidopa/levodopa (AP-CD/LD) failed to meet its primary endpoint in a Phase 3 trial for Parkinson’s disease (PD). Intec’s extended release AP-CD/LD failed to...

July 22, 2019

Developments

Theravance reports new Phase 2 data for ampreloxetine

Theravance Biopharma (NASDAQ:TPBH) reported new data from its Phase 2 trial of ampreloxetine in patients with neurogenic orthostatic hypotension (nOH). nOH is characterized by a fall in systolic or diastolic blood...

July 22, 2019

Developments

PharmaCyte and UTS creating advanced version of Melligen cells to treat diabetes

PharmaCyte Biotech (OTCQB:PMCB) entered into a new research agreement with the University of Technology Sydney (UTS) in Australia to create a new version of Melligen cells for the treatment of diabetes, with the...

July 22, 2019

Developments

Zenabis arranges $10-million of non-dilutive financing in supply pact with Starseed Medicinal

Zenabis Global (TSX:ZENA) entered into an agreement whereby Starseed Medicinal would advance $10-million to Zenabis in September 2019 in return for dried cannabis flower and trim from Zenabis. Under the accord, Zenabis...

July 22, 2019

Category - Developments

Myovant’s relugolix meets primary endpoint in Phase 3 uterine fibroid trial

Theralase in pact for U.S. clinical sites for Phase 2 NMIBC trial

Dawson James starts Anavex at buy: PT $16

Zenabis outperforms cannabis design capacity by 41% in June

Chiasma’s Mycapssa meets all endpoints in Phase 3 acromegaly trial

Emerging liver disease company, ContraVir, changes name to Hepion Pharmaceuticals; stock symbol to “HEPA”

Intec Parkinson’s disease candidate misses primary endpoint in Phase 3 trial

Theravance reports new Phase 2 data for ampreloxetine

PharmaCyte and UTS creating advanced version of Melligen cells to treat diabetes

Zenabis arranges $10-million of non-dilutive financing in supply pact with Starseed Medicinal

General

More